A 67-year-old male was diagnosed with a hepa-toma.After three sessions of camrelizumab plus chemo-therapy,there was an onset of dysphonia.As brain metastases and vocal cords disease were excluded,drug-related disorder was suspected and camrelizumab dosing discontinued.At Day 60,the symptom of hoarseness disappeared.Only 1 case of camrelizumab and 6 cases of other ICIs-related dysphonia have been described so far.Our case stood out for isolated dysphonia without any other adverse reactions of myopathy and infection.
NETL
